SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies

  • Org Study ID: TTX-030-001
  • Secondary ID:
  • NCT ID: NCT03884556
  • NCT Alias:
  • Sponsor: Trishula Therapeutics, Inc. - Industry
  • Source: Trishula Therapeutics, Inc.

Brief Summary

This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies.

Overal Status Start Date Phase Study Type
Recruiting April 10, 2019 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Recommended Phase 2 Dose (RP2D)

Primary Outcome 1 - Time Frame: 1 cycle (each cycle is 21-28 days)


  • Solid Tumor
  • Lymphoma


Abreviated Inclusion Criteria

1. Advanced solid tumor malignancy or relapsed/refractory lymphoma, or

- eligible to receive single-agent pembrolizumab as standard of care, or

- eligible to receive single-agent docetaxel as standard of care, or

- advanced pancreatic adenocarcinoma and eligible to receive gemcitabine plus
nab-paclitaxel as standard of care.

2. Age 18 years or older, is willing and able to provide informed consent

3. Evidence of measurable disease

4. Life expectancy > 12 weeks and Eastern Cooperative Oncology Group (ECOG) performance
status of 0-1

Abbreviated Exclusion Criteria

1. History of allergy or hypersensitivity to study treatment components. Patients with a
history of severe hypersensitivity reaction to any monoclonal antibody.

2. Use of investigational agent within 28 days prior to the first dose of study treatment
and throughout the study

3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive

4. History of severe autoimmune disease

5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Contact

Name: Trishula Therapeutics, Inc.

Phone: +1 888-480-0554



Facility Status Contact
UC Irvine Cancer Center
Orange, California 92868
United States
Recruiting Dorothy Chang
UC Davis Comprehensive Cancer Center
Sacramento, California 95817
United States
Recruiting Stacy Joo
University of California, San Francisco
San Francisco, California 94143
United States
Recruiting Cancer Immunotherapy program
Sylvester Comprehensive Cancer Center
Miami, Florida 33136
United States
Recruiting Isabel Fernandez, CCRC
Rush University Cancer Center
Chicago, Illinois 60612
United States
Recruiting Cancer Studies
Norton Cancer Institute
Louisville, Kentucky 40202
United States
Recruiting Ben Orem
Nebraska Cancer Center Oncology Hematology West P.C.
Omaha, Nebraska 68130
United States
Recruiting Megan Meays, M.A. CCRC
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08903
United States
Recruiting Olga Kovalenko
Montefiore Medical Center
Bronx, New York 10461
United States
Recruiting Mohammad Ghalib
Columbia University Irving Medical Center
New York, New York 10032
United States
Active, not recruiting
Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Active, not recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio 44122
United States
Recruiting Cancer Information Services
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania 15232
United States
Active, not recruiting
West Cancer Center and Research Institute
Germantown, Tennessee 38138
United States
Recruiting Amanda Fletcher
Sarah Cannon Research Institute
Nashville, Tennessee 37203
United States
Recruiting Referral Line
NEXT Oncology
San Antonio, Texas 78229
United States
Active, not recruiting
Huntsman Cancer Intitute
Salt Lake City, Utah 84112
United States
Recruiting Ashley Leary, RN, BSN